The quality-adjusted life-years loss due to serogroup B invasive meningococcal disease in Spain

被引:0
|
作者
Garcia, Andrea [1 ]
Vallejo-Aparicio, Laura A. [1 ]
Begum, Najida [2 ]
Nikitas, Georgios [3 ]
Gonzalez-Inchausti, Carmen [1 ]
de Gomensoro, Eduardo [1 ]
机构
[1] GSK, Tres Cantos, Spain
[2] Freelance C O GSK, Wavre, Belgium
[3] GSK, Wavre, Belgium
关键词
Invasive meningococcal disease; MenB; QALY loss; Spillover effect; Direct costs; Indirect costs; Spain; Humanistic burden; OF-LIFE; BURDEN; MENINGITIS; INFECTION; COST;
D O I
10.1016/j.vaccine.2024.126155
中图分类号
R392 [医学免疫学]; Q939.91 [免疫学];
学科分类号
100102 ;
摘要
Introduction: Despite its impact on a patient's life, there is a paucity of evidence on the humanistic burden of invasive meningococcal disease (IMD) due to serogroup B (MenB) in Spain. This study estimates the total quality-adjusted life-year (QALY) loss due to MenB-IMD in Spain from a societal perspective. Materials and methods: A previously published incidence-based Excel tool adapted to the Spanish setting was used to estimate total QALY losses over a patient's lifetime horizon, including direct and indirect impact on patients and families/caregivers, respectively. A 3% discount rate was applied, and a deterministic and probabilistic sensitivity analyses were performed to evaluate uncertainty and assumptions used for the base case. Results: The total discounted QALY loss for a hypothetical cohort of 142 cases of MenB-IMD was 572.44 QALYs (4.03/case). Direct loss (attributable to patients) represented 81.2% of the total loss (464.54 QALYs; 3.27/case) and indirect loss (caused to relatives/ caregivers) represented 18.8% (108.90 QALYs; 0.76/case). Sequelae had the highest impact on QALY loss for both patients (60.5%) and relatives/caregivers (84.6%). Children <5 years of age (YOA) accounted for 47.8% of the total QALY loss. Mortality accounted for 17.62 QALY loss per death. The discount rate parameter showed the highest influence on results and the probabilistic sensitivity analysis revealed a 98.0% probability of total QALY loss achieving the point estimate. Conclusions: The results emphasize that the humanistic burden associated with a MenB case is mainly driven by its sequelae, impacting the patients and their relatives/caregivers.
引用
下载
收藏
页数:7
相关论文
共 50 条
  • [1] QUALITY-ADJUSTED LIFE-YEARS
    SMITH, A
    LANCET, 1987, 2 (8549): : 47 - 47
  • [2] QUALITY-ADJUSTED LIFE-YEARS
    WILLIAMS, A
    LANCET, 1987, 1 (8546): : 1372 - 1372
  • [3] QUALITY-ADJUSTED LIFE-YEARS (QALYS) AND HUNTINGTON'S DISEASE
    Green, Colin
    Goodwin, Elizabeth
    Hawton, Annie
    JOURNAL OF NEUROLOGY NEUROSURGERY AND PSYCHIATRY, 2018, 89 : A49 - A49
  • [4] BURDEN OF DISEASE IN ASIAN COUNTRIES AND THE USE OF DISABILITY-ADJUSTED LIFE-YEARS AND QUALITY-ADJUSTED LIFE-YEARS
    Groom, Z. C.
    Beale, R. C.
    Brooks-Rooney, C.
    VALUE IN HEALTH, 2014, 17 (07) : A751 - A751
  • [5] The visibility and divisibility of quality-adjusted life-years
    Mullins, CD
    CLINICAL THERAPEUTICS, 2005, 27 (08) : 1276 - 1277
  • [6] Income-related inequality in life-years and quality-adjusted life-years
    Gerdtham, UG
    Johannesson, M
    JOURNAL OF HEALTH ECONOMICS, 2000, 19 (06) : 1007 - 1026
  • [7] Quality-Adjusted Life-Years without Constant Proportionality
    Craig, Benjamin M.
    Rand, Kim
    Bailey, Henry
    Stalmeier, Peep F. M.
    VALUE IN HEALTH, 2018, 21 (09) : 1124 - 1131
  • [8] Quality-Adjusted Life-Years Lost Due to Physical Inactivity in a US Population With Osteoarthritis
    Losina, Elena
    Silva, Genevieve S.
    Smith, Karen C.
    Collins, Jamie E.
    Hunter, David J.
    Shrestha, Swastina
    Messier, Stephen P.
    Yelin, Ed H.
    Suter, Lisa G.
    Paltiel, A. David
    Katz, Jeffrey N.
    ARTHRITIS CARE & RESEARCH, 2020, 72 (10) : 1349 - 1357
  • [9] Quantifying life: Understanding the history of Quality-Adjusted Life-Years (QALYs)
    MacKillop, Eleanor
    Sheard, Sally
    SOCIAL SCIENCE & MEDICINE, 2018, 211 : 359 - 366
  • [10] Methods and issues associated with the use of quality-adjusted life-years
    Revicki, Dennis A.
    Lenderking, William R.
    EXPERT REVIEW OF PHARMACOECONOMICS & OUTCOMES RESEARCH, 2012, 12 (01) : 105 - 114